Shenliu

Shenliu Biotech is an AI-driven biotechnology company headquartered in Shanghai, China, specializing in the de novo design and optimization of protein therapeutics. The company leverages its proprietary DeepFlow platform, which integrates deep learning, structural biology, and high-throughput screening to develop next-generation biologics with improved efficacy and reduced toxicity. Shenliu's primary focus is on engineering cytokines, such as IL-2 and IL-15 variants, for applications in oncology and immunology. By utilizing computational models to predict protein-protein interactions, the company aims to accelerate the drug discovery process and address unmet medical needs in complex diseases. The firm is backed by leading venture capital investors including Matrix Partners China and IDG Capital.